Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study

We investigated the efficacy and safety of dual bronchodilation with QVA149 versus its monocomponents indacaterol and glycopyrronium, tiotropium and placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). This was a multicentre, randomised, double-blind, placebo- and active-controlled, 26-week trial. Patients (n = 2144) were randomised (2:2:2:2:1) to receive once-daily QVA149 (indacaterol 110 &mgr;g/glycopyrronium 50 &mgr;g), indacaterol 150 &mgr;g, glycopyrronium 50 &mgr;g, open-label tiotropium 18 &mgr;g or placebo. The primary end-point was trough forced expiratory volume in 1 s (FEV1) at week 26 for QVA149 versus its monocomponents. Secondary end-points included dyspnoea, health status, rescue medication use and safety. Trough FEV1 at week 26 was significantly improved (p<0.001) with QVA149 compared with indacaterol and glycopyrronium (least squares mean (LSM) differences 0.07 L and 0.09 L, respectively), tiotropium and placebo (LSM differences 0.08 L and 0.20 L, respectively); these beneficial effects were sustained throughout the 26-week study. QVA149 significantly improved dyspnoea and health status versus placebo (p<0.001 and p = 0.002, respectively) and tiotropium (p = 0.007 and p = 0.009, respectively) at week 26. All treatments were well tolerated. Dual bronchodilation with once-daily QVA149 demonstrated superior and clinically meaningful outcomes versus placebo and superiority versus treatment with a single bronchodilator, with a safety and tolerability profile similar to placebo, supporting the concept of fixed-dose long-acting muscarinic antagonist/long-acting &bgr;2-agonist combinations for the treatment of COPD. Dual indacaterol/glycopyrronium therapy was safe and more efficacious than monotherapy in moderate-to-severe COPD http://ow.ly/p3H5E

[1]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. , 2001, Respiratory care.

[2]  J. Bourbeau,et al.  Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis , 2006, Thorax.

[3]  J. V. van Noord,et al.  QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease , 2010, Thorax.

[4]  K. Rabe,et al.  Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. , 2008, Chest.

[5]  E. Salpeter,et al.  Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. , 2004, Chest.

[6]  J. Bourbeau,et al.  Patient adherence in COPD , 2008, Thorax.

[7]  W. Bailey,et al.  Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.

[8]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[9]  D. Mahler,et al.  Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. , 2009, Respiratory medicine.

[10]  M. Cazzola,et al.  Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. , 2005, Drugs.

[11]  J. Wedzicha,et al.  Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.

[12]  J. Lammers,et al.  Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. , 2007, Respiratory medicine.

[13]  E. Bateman,et al.  Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison , 2012, Thorax.

[14]  J. V. van Noord,et al.  Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. , 2010, Respiratory medicine.

[15]  D. Tashkin,et al.  Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPD , 2009, COPD.

[16]  R. Cavallazzi,et al.  Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies , 2011, Thorax.

[17]  K. Hirata,et al.  Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial , 2011, Respiratory research.

[18]  M. Decramer,et al.  Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial , 2009, The Lancet.

[19]  J. V. van Noord,et al.  Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD , 2005, European Respiratory Journal.

[20]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[21]  A. Swensen,et al.  Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. , 2011, Respiratory medicine.

[22]  K. Verhamme,et al.  Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD. , 2012, Pulmonary pharmacology & therapeutics.

[23]  E. Bateman,et al.  Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. , 2013, The Lancet. Respiratory medicine.

[24]  E. Kerwin,et al.  Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study , 2012, European Respiratory Journal.

[25]  M. Cazzola,et al.  Inhaled β2-Adrenoceptor Agonists , 2012, Drugs.

[26]  C. Vogelmeier,et al.  Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. , 2008, Respiratory medicine.

[27]  D. Mahler,et al.  Minimal important difference of the transition dyspnoea index in a multinational clinical trial , 2003, European Respiratory Journal.

[28]  P. Jones,et al.  Measuring the effects of COPD on the patient. , 2005, Respiratory medicine.

[29]  J. Neder,et al.  Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. , 2010, Respiratory medicine.

[30]  T. Welte,et al.  Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD , 2009, European Respiratory Journal.

[31]  Dave Singh,et al.  Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial , 2012, International journal of chronic obstructive pulmonary disease.

[32]  C. Furberg,et al.  Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2008, JAMA.

[33]  V. Higgins,et al.  P185 Quantification and Treatment Patterns of Real-World Patients Classified by the GOLD 2011 Strategy , 2012, Thorax.

[34]  K. Ohta,et al.  Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. , 2007, Respiratory medicine.

[35]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[36]  L. Fabbri,et al.  Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD Patients , 2010, COPD.